HALAVEN® is the first and only single agent to show a significant overall survival benefit in patients with third-line metastatic breast cancer (mBC) that included all receptor subtypes.1-4
HALAVEN improved median overall survival in metastatic breast cancer vs Treatment of Physician's Choice (13.2 months vs 10.6 months) when following 2 prior chemotherapies for metastatic breast cancer.4
References: 1. Cortes J, O’Shaughnessy J, Loesch D, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-923. 2. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010;28(11):1958-1962. 3. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256-3263. 4. HALAVEN [package insert]. Nutley, NJ: Eisai Inc. 5. Data on file, Eisai Inc.